Abbott Laboratories

CGM sensor consumables and hospital diagnostics reagent contracts generate substantial repeat revenue, and Abbott's FY2025 total of $44.3B grew in every fiscal year from FY2020 through FY2025 including through COVID disruption and the subsequent diagnostics normalization. The devices segment is substantially procedure-linked rather than contracted, and no disclosed backlog metric confirms the 70%+ recurring threshold.

Abbott operates four genuinely distinct segments across medical devices, diagnostics, nutrition, and established pharmaceuticals, spanning different customer types and end markets. Medical Devices at 48% of FY2025 revenue represents a growing concentration that lands in the moderate range for a diversified healthcare conglomerate, with no segment below 12% but one segment clearly dominant.

International markets represent approximately 61% of FY2025 net sales, with the U.S. accounting for roughly 39% and emerging markets alone contributing 37% of total company sales. No single country exceeds 40% of revenue, and Abbott generates meaningful contributions from the Americas, Europe, and Asia-Pacific across all four product segments.

CGM sensor manufacturing and hospital diagnostics reagents benefit from volume-driven scale, and adjusted operating margin reached 25.8% in FY2025. Abbott's multi-segment industrial footprint requires ongoing capital investment across manufacturing, R&D, and direct sales forces, limiting the operating leverage achievable by asset-light platform businesses.

Hospital laboratories running Alinity analyzers depend on Abbott reagents for daily operations, providing steady mission-critical demand alongside a durable CGM sensor consumable stream. Medical devices revenue is largely tied to physician-driven procedures rather than contractual commitments, and the overall mix falls short of majority-subscription quality but is substantially more durable than transactional.